Disease Landscape and Forecast Insights

How Are Payers Reacting to Elevated Costs and How Will the Cost Trend Impact Specific Brands? The nation’s healthcare payers are using multilayered cost and utilization control strategies to…

Squamous cell carcinoma of the head and neck (SCCHN) is one of the six most frequently diagnosed malignancies worldwide. Second/third primary tumors are the main threats to long-term survival once…

Cervical cancer is reported to be the fourth most common form of cancer in women worldwide, despite the introduction of screening programs and vaccination programs against the virus known to cause…

Prevalence of the hepatitis C virus (HCV) in Brazil is estimated to be among the highest in the world; in addition, the country faces the challenge of treating a largely undiagnosed HCV-infected…

Cystic fibrosis (CF) is a genetic disease affecting chloride transport in a variety of tissues, most notably the lungs and pancreas, and is caused by mutations in the cystic fibrosis transmembrane…

Treatment for the wet (exudative, neovascular) form of age-related macular degeneration (AMD) in Europe is characterized by several current therapies targeting vascular endothelial growth factor (…

While Genentech’s Lucentis continues to be the gold-standard treatment for wet age-related macular degeneration (AMD) in the United States, off-label use of Genentech’s Avastin (often…

“TreatmentTrends: Dry/Wet Age-Related Macular Degeneration 2014 (EU)” is the third annual syndicated report that offers a snapshot of dry and wet age-related macular degeneration (AMD) market…

With biosimilar infliximab approved in Europe and filed for approval in the United States, rheumatologists and gastroenterologists will soon have the opportunity to prescribe biosimilars to their…

Muscular dystrophy (MD) is associated with degeneration and weakness of affected muscles that vary with the type of dystrophy. Dystrophies are characterized by common histological features such as…

The fledgling biosimilars industry is full of uncertainties and nuances that differ by country, therapeutic specialty, and molecule. Securing a positive return on lengthy biosimilar development…

As the pharmaceutical pipeline begins to churn out specialty products at a higher rate than traditional therapies, the nation’s healthcare payers are experiencing double-digit growth in their…